

Form PTO-1449

ATTY DOCKET NO.  
4614-0112PAPPLICATION NO.  
09/785,215**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**APPLICANT  
JENSEN, M. et al.FILING DATE  
February 20, 2001GROUP  
1647

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
CD	U.S. 5,192,688	<del>_____</del>	1993-03-09	SWITZER, III et al.	<del>_____</del>	<del>_____</del>	<del>_____</del>

**RECEIVED**

JUN 24 2003

TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

CD	McLAURIN, J. et al., Therapeutically effective antibodies against amyloid-B peptide target amyloid-B residues 4-10 and inhibit cytotoxicity and fibrillogenesis; Nature Medicine, published online 15 October 2002; doi:10.1038/nm790
↓	MONSONEGO, A. et al., Immune hyporesponsiveness to amyloid B-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease; PNAS, Aug. 28, 2001, vol. 98, no. 18, pp. 10273-10278
↓	Nature Medicine (NEWS), Vol. 8, Number 3, March 2002, pp. 199-200, 2002 Nature Publishing Group
CD	Nerve inflammation halts trial for Alzheimer's drug; Nature (news), Vol. 415, 31 January 2002

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

